688073 毕得医药
已收盘 07-09 15:00:01
资讯
新帖
简况
毕得医药（688073）披露2026年第二次临时股东会会议资料，7月9日股价上涨0.16%
证券之星 · 07-09 17:18
毕得医药（688073）披露2026年第二次临时股东会会议资料，7月9日股价上涨0.16%
7月8日毕得医药发布公告，股东减持118.49万股
证券之星 · 07-08 18:01
7月8日毕得医药发布公告，股东减持118.49万股
7月8日毕得医药跌8.42%，信澳信用债债券A基金重仓该股
证券之星 · 07-08 16:29
7月8日毕得医药跌8.42%，信澳信用债债券A基金重仓该股
7月7日毕得医药现4笔大宗交易 机构净买入506.8万元
证券之星 · 07-07 17:35
7月7日毕得医药现4笔大宗交易 机构净买入506.8万元
每周股票复盘：毕得医药（688073）调整激励计划授予权益
证券之星 · 07-05
每周股票复盘：毕得医药（688073）调整激励计划授予权益
7月2日毕得医药跌5.95%，信澳信用债债券A基金重仓该股
证券之星 · 07-02
7月2日毕得医药跌5.95%，信澳信用债债券A基金重仓该股
股市必读：6月30日毕得医药发生1笔大宗交易 成交金额263.74万元
证券之星 · 07-01
股市必读：6月30日毕得医药发生1笔大宗交易 成交金额263.74万元
毕得医药（688073）披露2024年限制性股票激励计划首次授予及预留授予部分第一个归属期符合归属条件的公告，6月30日股价下跌0.77%
证券之星 · 06-30
毕得医药（688073）披露2024年限制性股票激励计划首次授予及预留授予部分第一个归属期符合归属条件的公告，6月30日股价下跌0.77%
股市必读：6月29日毕得医药现580.04万元大宗交易
证券之星 · 06-30
股市必读：6月29日毕得医药现580.04万元大宗交易
股市必读：毕得医药（688073）6月26日董秘有最新回复
证券之星 · 06-29
股市必读：毕得医药（688073）6月26日董秘有最新回复
毕得医药：分子砌块及科学试剂重要性进一步提升
证券之星 · 06-26
毕得医药：分子砌块及科学试剂重要性进一步提升
6月23日毕得医药涨5.16%，信澳信用债债券A基金重仓该股
证券之星 · 06-23
6月23日毕得医药涨5.16%，信澳信用债债券A基金重仓该股
每周股票复盘：毕得医药（688073）董事会秘书王轩因个人原因离任
证券之星 · 06-20
每周股票复盘：毕得医药（688073）董事会秘书王轩因个人原因离任
毕得医药（688073）披露董事会秘书离任公告，6月17日股价下跌1.54%
证券之星 · 06-17
毕得医药（688073）披露董事会秘书离任公告，6月17日股价下跌1.54%
每周股票复盘：毕得医药（688073）现两日大宗折价交易
证券之星 · 06-14
每周股票复盘：毕得医药（688073）现两日大宗折价交易
毕得医药：多快好省分别指多样试剂选择、快速交付服务、高质量产品保证、省心成本优化
证券之星 · 06-12
毕得医药：多快好省分别指多样试剂选择、快速交付服务、高质量产品保证、省心成本优化
6月11日毕得医药现1笔折价19.2%的大宗交易 合计成交236.86万元
证券之星 · 06-11
6月11日毕得医药现1笔折价19.2%的大宗交易 合计成交236.86万元
每周股票复盘：毕得医药（688073）股东拟合计减持不超3.00%股份
证券之星 · 05-24
每周股票复盘：毕得医药（688073）股东拟合计减持不超3.00%股份
5月20日毕得医药涨6.19%，信澳信用债债券A基金重仓该股
证券之星 · 05-20
5月20日毕得医药涨6.19%，信澳信用债债券A基金重仓该股
毕得医药涨6.19%，开源证券二个月前给出“买入”评级
证券之星 · 05-20
毕得医药涨6.19%，开源证券二个月前给出“买入”评级
加载更多
公司概况
公司名称：
上海毕得医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-10-11
主营业务：
上海毕得医药科技股份有限公司的主营业务是药物分子砌块和科学试剂的研发、设计、生产及销售。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块脂肪族类化合物、催化剂和配体、生命科学试剂。截至报告期末，公司知识产权项目获得授权数量148个，其中发明专利59个，实用新型专利24个，外观设计专利1个，软件著作权2个，其他62个。
发行价格：
88.00
{"stockData":{"symbol":"688073","market":"SH","secType":"STK","nameCN":"毕得医药","latestPrice":49.98,"timestamp":1783580401000,"preClose":49.9,"halted":0,"volume":3639120,"delay":0,"changeRate":0.0016,"floatShares":90882900,"shares":90882900,"eps":1.8472,"marketStatus":"已收盘","change":0.08,"latestTime":"07-09 15:00:01","open":49.55,"high":51.6,"low":48.33,"amount":181000000,"amplitude":0.0655,"askPrice":49.98,"askSize":4,"bidPrice":49.92,"bidSize":10,"shortable":0,"etf":0,"ttmEps":1.8472,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783647000000},"marketStatusCode":5,"adr":0,"adjPreClose":49.9,"symbolType":"stock_kcb","openAndCloseTimeList":[[1783560600000,1783567800000],[1783573200000,1783580400000]],"highLimit":54.89,"lowLimit":44.91,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":90882948,"isCdr":false,"pbRate":2.16,"roa":"--","peRate":27.057168,"roe":"2.26%","epsLYR":1.75,"committee":0.760563,"marketValue":4542000000,"turnoverRate":0.04,"status":0,"afterMarket":{"amount":0,"volume":0,"close":49.98,"buyVolume":0,"sellVolume":0,"time":1783582437746,"indexStatus":"已收盘 07-09 15:30:00","preClose":49.9},"floatMarketCap":4542000000},"requestUrl":"/m/hq/s/688073","defaultTab":"news","newsList":[{"id":"2650409849","title":"毕得医药（688073）披露2026年第二次临时股东会会议资料，7月9日股价上涨0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650409849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650409849?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:18","pubTimestamp":1783588680,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，毕得医药报收于49.98元，较前一交易日上涨0.16%，最新总市值为45.42亿元。该股当日开盘49.55元，最高51.6元，最低48.33元，成交额达1.81亿元，换手率为4.0%。近日，毕得医药发布2026年第二次临时股东会会议资料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900030259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649889967","title":"7月8日毕得医药发布公告，股东减持118.49万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649889967","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649889967?lang=zh_cn&edition=full","pubTime":"2026-07-08 18:01","pubTimestamp":1783504896,"startTime":"0","endTime":"0","summary":"证券之星消息，7月8日毕得医药发布公告《毕得医药:关于股东权益变动触及1%刻度的提示性公告》，其股东舟山欣曦企业管理合伙企业(有限合伙)、舟山兰旦企业管理合伙企业(有限合伙)于2026年6月29日至2026年7月7日间合计减持118.49万股，占公司目前总股本的1.3037%，变动期间该股股价上涨9.64%，截止7月7日收盘报54.49元。股东增减持详情见下表：根据毕得医药2026年一季报公布的十大股东详情如下：本文数据来源于毕得医药公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800032807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649697899","title":"7月8日毕得医药跌8.42%，信澳信用债债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649697899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649697899?lang=zh_cn&edition=full","pubTime":"2026-07-08 16:29","pubTimestamp":1783499346,"startTime":"0","endTime":"0","summary":"证券之星消息，7月8日毕得医药跌8.42%，收盘报49.9元，换手率4.6%，成交量4.18万手，成交额2.15亿元。重仓毕得医药的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为信达澳亚基金的信澳信用债债券A。信澳信用债债券A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800029177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","159397","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649986586","title":"7月7日毕得医药现4笔大宗交易 机构净买入506.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649986586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649986586?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:35","pubTimestamp":1783416946,"startTime":"0","endTime":"0","summary":"证券之星消息，7月7日毕得医药发生大宗交易，交易数据如下：近三个月该股共发生33笔大宗交易，合计成交1.85万手，折价成交33笔。该股在过去半年内已有共计4764.88万股限售解禁股上市，占公司总股本的52.43%。截至2026年7月7日收盘，毕得医药(688073)报收于54.49元，下跌2.56%，换手率3.08%，成交量2.8万手，成交额1.53亿元。该股近半年内有股东持股变动，合计净减持189.86万股，股东增减持明细如下表：该股最近90天内共有3家机构给出评级，买入评级3家。本文数据来源于上海证券交易所大宗交易信息披露，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700030063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649694175","title":"每周股票复盘：毕得医药（688073）调整激励计划授予权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2649694175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649694175?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:29","pubTimestamp":1783189750,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，毕得医药报收于54.51元，较上周的49.7元上涨9.68%。来自公司公告汇总：毕得医药调整限制性股票激励计划授予价格至22.90元/股。交易信息汇总6月30日毕得医药发生1笔大宗交易，成交金额263.74万元。本次调整符合法律法规及激励计划规定，不构成对公司财务状况和经营成果的重大影响。2024年限制性股票激励计划首次授予及预留授予部分第一个归属期归属条件已成就。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648508576","title":"7月2日毕得医药跌5.95%，信澳信用债债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648508576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648508576?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:32","pubTimestamp":1782981166,"startTime":"0","endTime":"0","summary":"证券之星消息，7月2日毕得医药跌5.95%，收盘报52.51元，换手率3.82%，成交量3.47万手，成交额1.89亿元。重仓毕得医药的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为信达澳亚基金的信澳信用债债券A。信澳信用债债券A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200027049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159397","BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648569598","title":"股市必读：6月30日毕得医药发生1笔大宗交易 成交金额263.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648569598","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648569598?lang=zh_cn&edition=full","pubTime":"2026-07-01 03:05","pubTimestamp":1782846313,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，毕得医药报收于53.82元，下跌0.77%，换手率2.7%，成交量2.45万手，成交额1.31亿元。公司公告汇总：董事会审议通过2024年限制性股票激励计划首次及预留授予部分第一个归属期归属事项，58名激励对象合计可归属111.2012万股。公司公告汇总：公司将于2026年7月16日召开2026年第二次临时股东大会，股权登记日为7月8日。大宗交易6月30日毕得医药发生1笔大宗交易，成交金额263.74万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100001764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647521175","title":"毕得医药（688073）披露2024年限制性股票激励计划首次授予及预留授予部分第一个归属期符合归属条件的公告，6月30日股价下跌0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647521175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647521175?lang=zh_cn&edition=full","pubTime":"2026-06-30 22:24","pubTimestamp":1782829464,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，毕得医药报收于53.82元，较前一交易日下跌0.77%，最新总市值为48.91亿元。公告显示，公司2024年限制性股票激励计划首次授予及预留授予部分第一个归属期归属条件已成就。公司于2026年6月30日召开董事会审议通过相关议案，本次可归属限制性股票数量为111.2012万股，其中首次授予部分90.2500万股，预留授予部分20.9512万股。58名激励对象中，个人绩效考核结果均为合格，个人层面归属比例为100%。另有部分限制性股票因离职或放弃被作废。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000047149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647637306","title":"股市必读：6月29日毕得医药现580.04万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2647637306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647637306?lang=zh_cn&edition=full","pubTime":"2026-06-30 00:57","pubTimestamp":1782752230,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘，毕得医药报收于54.24元，上涨9.13%，换手率4.62%，成交量4.2万手，成交额2.18亿元。当日关注点交易信息汇总：6月29日主力资金净流入2355.49万元； 交易信息汇总：当日发生580.04万元大宗交易。大宗交易6月29日毕得医药发生580.04万元大宗交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000000761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647343776","title":"股市必读：毕得医药（688073）6月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2647343776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647343776?lang=zh_cn&edition=full","pubTime":"2026-06-29 03:49","pubTimestamp":1782676150,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，毕得医药报收于49.7元，上涨1.64%，换手率3.44%，成交量3.13万手，成交额1.57亿元。董秘最新回复投资者： 您好，请问，人工智能的出现和发展，使得研制新药的效率提高。当日关注点交易信息汇总：6月26日主力资金净流入660.42万元，游资资金净流入158.61万元，散户资金净流出819.03万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900001181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646816330","title":"毕得医药：分子砌块及科学试剂重要性进一步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2646816330","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646816330?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:24","pubTimestamp":1782462250,"startTime":"0","endTime":"0","summary":"证券之星消息，毕得医药06月26日在投资者关系平台上答复投资者关心的问题。谢谢毕得医药回复：投资者你好。人工智能等技术在药物研发中的应用逐步增加，在分子设计、靶点筛选等环节提供辅助支持，同时也对上游分子砌块及试剂的结构丰富度及合成能力提出更高要求。在此背景下，分子砌块及科学试剂在新药研发过程中的重要性进一步提升，相关产品在支持药物筛选、结构优化及实验验证等方面的作用不断增强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600029734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645388101","title":"6月23日毕得医药涨5.16%，信澳信用债债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645388101","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645388101?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:50","pubTimestamp":1782204634,"startTime":"0","endTime":"0","summary":"证券之星消息，6月23日毕得医药涨5.16%，收盘报48.67元，换手率2.45%，成交量2.23万手，成交额1.07亿元。重仓毕得医药的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为信达澳亚基金的信澳信用债债券A。信澳信用债债券A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073","159397"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644065639","title":"每周股票复盘：毕得医药（688073）董事会秘书王轩因个人原因离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2644065639","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644065639?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:58","pubTimestamp":1781895490,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：董事会秘书王轩因个人原因辞去职务，由董事长戴岚代行职责公司公告汇总关于董事会秘书离任的公告上海毕得医药科技股份有限公司董事会于2026年6月17日收到董事会秘书王轩女士的书面辞职报告，王轩女士因个人原因辞去董事会秘书职务，辞职后不再担任公司任何职务。王轩女士未持有公司股份，已获授但尚未归属的60,000股限制性股票将按相关规定处理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644837747","title":"毕得医药（688073）披露董事会秘书离任公告，6月17日股价下跌1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644837747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644837747?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:58","pubTimestamp":1781708295,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，毕得医药报收于44.63元，较前一交易日下跌1.54%，最新总市值为40.56亿元。近日，毕得医药发布《关于董事会秘书离任的公告》。公告显示，公司董事会于2026年6月17日收到董事会秘书王轩女士的书面辞职报告，王轩女士因个人原因辞去董事会秘书职务，辞职后不再担任公司任何职务。王轩女士未持有公司股份，已获授但尚未归属的60,000股限制性股票将按相关规定处理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643217268","title":"每周股票复盘：毕得医药（688073）现两日大宗折价交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2643217268","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643217268?lang=zh_cn&edition=full","pubTime":"2026-06-14 01:43","pubTimestamp":1781372591,"startTime":"0","endTime":"0","summary":"截至2026年6月12日收盘，毕得医药报收于46.13元，较上周的47.89元下跌3.68%。本周，毕得医药6月8日盘中最高价报47.76元。本周关注点交易信息汇总：6月10日至11日毕得医药连续两日发生折价约19%的大宗交易。股本股东变化：股东舟山欣曦、舟山兰旦合计减持19.5万股，占总股本0.2145%。6月10日XD毕得医发生2笔折价19.39%的大宗交易，合计成交477.36万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061400000394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462261","title":"毕得医药：多快好省分别指多样试剂选择、快速交付服务、高质量产品保证、省心成本优化","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462261","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642462261?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:48","pubTimestamp":1781257718,"startTime":"0","endTime":"0","summary":"以及5.20的股东人数毕得医药回复：投资者你好，“多、快、好、省”主要体现在如下方面：1、多：“多”样的试剂选择。为客户提供常规试剂和定制化产品采购方案。我们依托高效的物流体系，全球各地现货仓库同步运行，迅速完成发货交付，同时提供加急配送服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200028140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642292288","title":"6月11日毕得医药现1笔折价19.2%的大宗交易 合计成交236.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642292288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642292288?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:31","pubTimestamp":1781170316,"startTime":"0","endTime":"0","summary":"证券之星消息，6月11日毕得医药发生大宗交易，交易数据如下：大宗交易成交价格36.44元，相对当日收盘价折价19.2%，成交6.5万股，成交金额236.86万元，买方营业部为兴业证券股份有限公司上海金陵东路证券营业部，卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。近三个月该股共发生26笔大宗交易，合计成交1.3万手，折价成交26笔。截至2026年6月11日收盘，毕得医药报收于45.1元，下跌0.99%，换手率0.63%，成交量5686.0手，成交额2555.75万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100027938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637761003","title":"每周股票复盘：毕得医药（688073）股东拟合计减持不超3.00%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2637761003","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637761003?lang=zh_cn&edition=full","pubTime":"2026-05-24 05:06","pubTimestamp":1779570375,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，毕得医药报收于55.4元，较上周的55.25元上涨0.27%。欣曦管理拟减持不超过1,363,243股，兰旦管理拟减持不超过1,181,477股，吴波拟减持不超过181,766股，合计减持比例不超过公司总股本的3.00%。上述股东为一致行动人，合计持有公司7.16%股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636812318","title":"5月20日毕得医药涨6.19%，信澳信用债债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636812318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636812318?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:26","pubTimestamp":1779265615,"startTime":"0","endTime":"0","summary":"证券之星消息，5月20日毕得医药涨6.19%，收盘报55.21元，换手率3.35%，成交量3.04万手，成交额1.64亿元。重仓毕得医药的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为信达澳亚基金的信澳信用债债券A。信澳信用债债券A目前规模为24.39亿元，最新净值1.359，较上一交易日上涨0.82%，近一年上涨21.34%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000029438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159397","BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636881258","title":"毕得医药涨6.19%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2636881258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636881258?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:26","pubTimestamp":1779265603,"startTime":"0","endTime":"0","summary":"今日毕得医药涨6.19%，收盘报55.21元。2026年3月2日，开源证券研究员余汝意,石启正发布了对毕得医药的研报《公司信息更新报告：2025年业绩表现亮眼，经营态势稳步向好》，该研报对毕得医药给出“买入”评级。研报中预计公司2025-2027年归母净利润为1.52/2.27/2.84亿，对应EPS分别为1.68/2.50/3.13元/股，当前股价对应PE为34.8/23.3/18.6倍，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为华创证券的万梦蝶。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000029435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688073"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783635316071,"stockEarnings":[{"period":"1week","weight":-0.0482},{"period":"1month","weight":0.0889},{"period":"3month","weight":-0.1833},{"period":"6month","weight":-0.262},{"period":"1year","weight":-0.1484},{"period":"ytd","weight":-0.1617}],"compareEarnings":[{"period":"1week","weight":0.0019},{"period":"1month","weight":0.0066},{"period":"3month","weight":0.0126},{"period":"6month","weight":-0.0203},{"period":"1year","weight":0.1556},{"period":"ytd","weight":0.0171}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海毕得医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"4924人(较上一季度增加26.52%)","perCapita":"18457股","listingDate":"2022-10-11","address":"上海市杨浦区翔殷路128号11号楼A座101室","registeredCapital":"9088万元","survey":" 上海毕得医药科技股份有限公司的主营业务是药物分子砌块和科学试剂的研发、设计、生产及销售。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块脂肪族类化合物、催化剂和配体、生命科学试剂。截至报告期末，公司知识产权项目获得授权数量148个，其中发明专利59个，实用新型专利24个，外观设计专利1个，软件著作权2个，其他62个。","listedPrice":88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"毕得医药,688073,毕得医药股票,毕得医药股票老虎,毕得医药股票老虎国际,毕得医药行情,毕得医药股票行情,毕得医药股价,毕得医药股市,毕得医药股票价格,毕得医药股票交易,毕得医药股票购买,毕得医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}